Active ingredient
- lenalidomide
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: Pl17780/0862.
Lenalidomide hard capsules - all strengths
Package leaflet: Information for the patient
Lenalidomide 5 mg hard capsules
Lenalidomide 10 mg hard capsules
Lenalidomide 15 mg hard capsules
Lenalidomide 25 mg hard capsules
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What lenalidomide is and what it is used for
2. What you need to know before you take lenalidomide
3. How to take lenalidomide
4. Possible side effects
5. How to store lenalidomide
6. Contents of the pack and other information
1. What lenalidomide is and what it is used for
The name of the product is Lenalidomide hard capsules (called lenalidomide throughout this leaflet). The capsules contain the active substance lenalidomide. This medicine belongs to a group of medicines which affect how your immune system works.
Lenalidomide is used in adults for:
Multiple myeloma
Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell.
These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.
Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a ‘response’.
Newly diagnosed multiple myeloma – in patients who have had a bone marrow transplant
Lenalidomide is used on its own as maintenance therapy after patients have recovered enough following a bone marrow transplant.
Newly diagnosed multiple myeloma – in patients who cannot have a bone marrow transplant
Lenalidomide is taken with other medicines. These may include:
You will take these other medicines at the start of treatment and then continue to take lenalidomide on its own.
If you are aged 75 years or older or have moderate to severe kidney problems – your doctor will check you carefully before starting treatment.
Multiple myeloma – in patients who have had treatment before
Lenalidomide is taken together with an anti-inflammatory medicine called dexamethasone.
Lenalidomide can stop the signs and symptoms of multiple myeloma getting worse. It has also been shown to delay multiple myeloma from coming back following treatment.
Myelodysplastic syndromes (MDS)
MDS are a collection of many different blood and bone marrow diseases. The blood cells become abnormal and do not function properly. Patients can experience a variety of signs and symptoms including a low red blood cell count (anaemia), the need for a blood transfusion, and be at risk of infection.
Lenalidomide is used alone to treat adult patients who have been diagnosed with MDS, when all of the following apply:
Lenalidomide can increase the number of healthy red blood cells that the body produces by reducing the number of abnormal cells:
Mantle cell lymphoma (MCL)
MCL is a cancer of part of the immune system (the lymph tissue). It affects a type of white blood cell called B-lymphocytes or B-cells. MCL is a disease where B-cells grow in an uncontrolled way and build up in the lymph tissue, bone marrow or blood.
Lenalidomide is used alone to treat adult patients who have previously been treated with other medicines.
Follicular lymphoma (FL)
FL is a slow growing cancer that affects the B-lymphocytes.
These are a type of white blood cells that help your body fight infection. When you have FL, too many of these B-lymphocytes may collect in your blood, bone marrow,
lymph nodes and spleen.
Lenalidomide is taken together with another medicine called rituximab for the treatment of adult patients with previously treated follicular lymphoma.
How lenalidomide works
Lenalidomide works by affecting the body’s immune system and directly attacking the cancer. It works in a number of different ways:
2. What you need to know before you take lenalidomide
You must read the package leaflet of all medicinal products to be taken in combination with lenalidomide before starting treatment with lenalidomide.
Do not take lenalidomide if you are:
If any of these apply to you, do not take lenalidomide. Talk to your doctor if you are not sure.
Warnings and precautions
Talk to your doctor or pharmacists before taking lenalidomide if you have:
If any of the above apply to you, tell your doctor or pharmacist before starting treatment.
At any time during or after your treatment, tell your doctor or nurse immediately if you experience:
Tests and checks
Before and during the treatment with lenalidomide you will have regular blood tests. This is because lenalidomide may cause a fall in the blood cells that help fight infection (white blood cells) and help the blood to clot (platelets). Your doctor will ask you to have a blood test:
You may be evaluated for signs of cardiopulmonary problems before and during the treatment with lenalidomide.
For patients with MDS taking lenalidomide
If you have MDS, you may be more likely to get a more advanced condition called acute myeloid leukaemia (AML). In addition, it is not known how lenalidomide affects the chances of you getting AML. Your doctor may therefore do tests to check for signs which may better predict the likelihood of you getting AML during your treatment with lenalidomide.
For patients with MCL taking lenalidomide
Your doctor will ask you to have a blood test:
For patients with FL taking lenalidomide
Your doctor will ask you to have a blood test:
Your doctor may check if you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the blood which can lead to kidney failure (this condition is called ‘tumour lysis syndrome’).
Your doctor may check you for changes to your skin such as red spots or rashes.
Your doctor may adjust your dose of lenalidomide or stop your treatment based on the results of your blood tests and on your general condition. If you are newly diagnosed, your doctor may also assess your treatment based on your age and other conditions you already have.
Blood donation
You should not donate blood during treatment and for at least 7 days after the end of treatment.
Children and adolescents
Lenalidomide is not recommended for use in children and adolescents under 18 years.
Elderly and people with kidney problems
If you are aged 75 years or older or have moderate to severe kidney problems – your doctor will check you carefully before starting treatment.
Other medicines and lenalidomide
Tell your doctor or nurse if you are taking or have recently taken any other medicines. This is because lenalidomide can affect the way some other medicines work. Also, some other medicines can affect the way lenalidomide works.
In particular, tell your doctor or nurse if you are taking any of the following medicines:
Pregnancy, breast-feeding and contraception – information for women and men
Pregnancy
For women taking lenalidomide
For men taking lenalidomide
Breast-feeding
You must not breast-feed when taking lenalidomide, as it is not known if lenalidomide passes into breast milk.
Contraception
For women taking lenalidomide
Before starting the treatment, ask your doctor if you are able to become pregnant, even if you think this is unlikely.
If you are able to become pregnant:
AND
For men taking lenalidomide
Lenalidomide passes into human semen. If your female partner is pregnant or able to become pregnant, and she does not use effective methods of contraception, you must use condoms during treatment and for at least 7 days after the end of treatment, even if you have had a vasectomy.
Driving and using machines
Do not drive or operate machines if you feel dizzy, tired, sleepy, have vertigo or blurred vision after taking lenalidomide.
Lenalidomide contains lactose and sodium
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially “sodium-free”.
3. How to take lenalidomide
Lenalidomide must be given to you by healthcare professionals with experience in treating multiple myeloma, MDS, MCL or FL.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
If you are taking lenalidomide in combination with other medicines, you should refer to the package leaflets for these medicines for further information on their use and effects.
Treatment cycle
Lenalidomide is taken on certain days over 3 weeks (21 days).
OR
How much lenalidomide to take
Before you start treatment, your doctor will tell you:
How and when to take lenalidomide
Taking this medicine
To remove the capsule from the blister:
Duration of the treatment with lenalidomide
Lenalidomide is taken in treatment cycles, each cycle lasting 21 or 28 days (see above “Treatment cycle”). You should continue the cycles of treatment until your doctor tells you to stop.
If you take more lenalidomide than you should
If you take more lenalidomide than was prescribed, tell your doctor immediately.
If you forget to take lenalidomide
If you forget to take lenalidomide at your regular time and
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking lenalidomide and see a doctor straight away if you notice any of the following serious side effects – you may need urgent medical treatment.
Also tell your doctor straight away if you notice any of the following serious side effects:
Lenalidomide may reduce the number of white blood cells that fight infection, red blood cells which carry oxygen and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders such as nosebleeds and bruising. Lenalidomide may also cause blood clots in the veins (thrombosis).
Other side effects
It is important to note that a small number of patients may develop additional types of cancer, and it is possible that this risk may be increased with lenalidomide treatment, therefore your doctor should carefully evaluate the benefit and risk when you are prescribed lenalidomide.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the MHRA Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store lenalidomide
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date, which is stated on the blister and on the carton after “EXP”. The expiry date refers to the last day of that month.
This product does not require any special storage conditions.
Do not use this medicine if you notice any damage or signs of tampering to the pack.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to through away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What lenalidomide contains
The active substance is lenalidomide. Each capsule contains 5, 10, 15, or 25 mg of lenalidomide.
The other ingredients are:
Capsule contents: Lactose; cellulose, microcrystalline (E460 (i); croscarmellose sodium (E468); magnesium stearate (E470b).
Capsule shell: Gelatine, titanium dioxide (E171)
Printing ink: Shellac (E904); propylene glycol (E1502); black iron oxide (E172); potassium hydroxide.
What lenalidomide looks like and contents of the pack
Lenalidomide 5 mg hard capsules: Opaque white body and opaque white cap, with a length of approximately 18.0 mm, marked “L9NL” and “5”.
Lenalidomide 10 mg hard capsules: Opaque yellow body and opaque green to light green cap, with a length of approximately 21.7 mm, marked “L9NL” and “10”.
Lenalidomide 15 mg hard capsules: Opaque white body and opaque blue cap to light blue, with a length of approximately 21.7 mm, marked“L9NL” and “15”.
Lenalidomide 25 mg hard capsules: Opaque white body and opaque white cap, with a length of approximately 21.7 mm, marked “L9NL” and “25”.
Boxes contain 7 or 21 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer(s):
Or
This leaflet was last revised in August 2021
1065026603
12 New Fetter Lane, LONDON, EC4A 1JP, UK
+44 (0)800 090 2408
+44 (0)844 8793 188